Morningstar

Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma

Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...
News Medical

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
Cure Today

First Patient with CD5-Positive T-Cell Lymphoma Dosed with MB-105

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
Seeking Alpha

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

MIRAMAR, Fla., Sept. 09, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc., a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen ...
PharmiWeb

Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation Technologies

Press ReleaseIB [email protected] Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation TechnologiesTechnology based on Bracco’s clinically validated ...
Hosted on MSN

Five-patient lupus CAR T-cell feasibility test claims positive short-term results

Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...